SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs has drawn attention, with traders citing BRIUMVIs sales growth and the Q3 results and subcutaneous Phase 3 data as key business catalysts. Buyout speculationparticularly involving Sanofiand hopes for short covering are widespread, but no deal is confirmed; some investors argue that execution matters more than takeover chatter.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is discussing access to a large number of U.S. cell sites have focused attention on Crown Castle as traders weigh potential new tower-leasing demand for Starlink Mobile. Bulls see a hybrid satellite-and-terrestrial network as a boost for tower owners, while skeptics note that no agreement is signed and question execution, regulatory approval, and whether speculation has already driven the move.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,967,326.643147 in circulation. The last known price of Algorand is 0.09515711 USD and is down -0.23 over the last 24 hours. It is currently trading on 586 active market(s) with $49,581,617.87 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention around a contested recovery thesis: bullish traders cite technical support, rebounds and a possible altcoin rotation, while bears point to persistent underperformance and the risk of further declines. Some bulls also highlight Algorands quantum-resistant technology and tokenization or payment use cases, though these are longer-term narratives rather than a confirmed near-term catalyst.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

A volatile LINK rebound and repeated resistance tests are driving discussion, with bulls pointing to Chainlinks institutional and tokenization integrations, including its role in Coinbases Base tokenized-stock offering and CCIP 2.0. Skeptics warn that rallies have faded before and question whether network adoption will translate into value for the LINK token.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

BTDR is under pressure alongside Bitcoin miners and AI infrastructure stocks as traders cite Bitcoin weakness and a recent downgrade; some also blame short-selling, though that remains speculation. The community is split between calling the selloff an opportunity ahead of earnings and worrying the decline could continue, with many frustrated by BTDRs lagging performance versus peers.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas upcoming addition to the S&P 500 is a major topic, with traders weighing expected index-fund buying against a possible sell-the-news move as the shares weaken. Some posts also cite an alleged DHS-related breach, but those claims are unverified in the discussion.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans strong third-quarter results, higher full-year outlook and record backlog are driving discussion, with traders pointing to sustained defense demand. The reaction is mixed: some see the fundamentals as support for the shares, while others question the rally and expect a pullback.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is drawing attention after dazodalibep met its Phase 3 endpoint in Sjgrens disease, with traders viewing the result as a pipeline catalyst. The discussion also cites strong IMDELLTRA/Imfinzi small-cell lung cancer data, alongside questions about whether recent momentum is already priced in.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

A newly disclosed performance-based option award for CEO Gregory Demopulos is drawing attention, with traders debating whether its stock-price and service conditions align his incentives with shareholders. The broader discussion remains focused on YARTEMLEAs U.S. sales growth and the next quarterly results, with bullish expectations balanced by caution after the European regulatory rejection.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of expected Q4 topline results from its Phase 3 HLP003 trial for major depressive disorder, a pivotal catalyst for the clinical-stage biotech. Traders are optimistic about the treatments potential as an add-on to existing antidepressants, but debate the binary trial risk, possible dilution and how results could compare with peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top-Performing International ETFs of 2025

International ETFs like VEA, EZU & EEM outshone U.S. peers in 2025 as cheaper valuations, diversified exposure, and stimulus measures drove substantial gains.

U.S. Equities Lag International in 2025: 5 Top ETF Performers 

International ETFs like FDT, IDV, FDTS, EFAS & FLEU soared as investors pivot from pricey and uncertain policy-driven U.S. markets to undervalued international plays.

Stellantis Production In Italy Slumps 27% In H1 2025: Union Now Expects Slump In Annual Numbers

Equity

The union expects the carmaker to produce 440,000 vehicles across its six assembly plants in Italy this year, including 250,000 passenger cars.

US Regulator Initiates Recall Query Into Nearly 1.2M Stellantis Ram Trucks: Retail Sentiment Dips

NHTSA said that it received 14 vehicle owner questionnaire reports and six death and injury reports under its Early Warning Reporting program describing failures of the Brake
Transmission Shift Interlock (BTSI) system.

Stellantis’ US Sales Drop Results In Downgrade At Wolfe, Firm Flags ‘Meaningful Risk’ To 2025, 2026 Earnings

Wolfe models about a €1 billion loss in North America this year, versus the consensus call for a roughly €1.6 billion profit, and added that "even this may be optimistic."

Best-Performing Dividend ETFs of 1H

FDD and EFAS surged over 30% in H1 2025 as investors turned to global dividend ETFs amid U.S. market volatility.

Global X Funds - Global X MSCI SuperDividend EAFE ETF

Neutral Sentiment

Jeep parent Stellantis NV’s (STLA) production in Italy fell by 27% to 221,885 vehicles in the first half of 2025, union Fim CISL said on Monday.While the company’s passenger car production in Italy recorded a decrease of about 34% to 123,905 units, commercial vehicle production <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fim-cisl.it/2025/07/07/stellantis-uliano-report-produzione-e-occupazione-1semestre-2025-26-9-tutti-gli-stabilimenti-in-negativo/">fell</a> by about 16% to 97,980 units.The union expects the carmaker to produce 440,000 vehicles across its six assembly plants in Italy this year, including 250,000 passenger cars.Union head Ferdinando Uliano noted that the data shows further worsening as compared to an already critical 2024. In 2024, <a href="https://stocktwits.com/symbol/STLA">Stellantis</a> produced 475,090 vehicles in Italy, marking a dip of 37% year-on-year and including 283,090 passenger cars.Production fell across the company’s six final production plants in Italy in the six months through the end of June, unlike in the first half of 2024, when at least the Pomigliano factory experienced an increase in production.While Pomigliano recorded the highest production among the six plants in the first half of 2025, it marked a fall of about 24% YoY. The Maserati Modena plant manufactured only 45 units in the period, marking a decline of about 72%.Uliano noted that there are no signs of recovery by the end of the year, as the start of production of the hybrid Fiat 500 later this year at the Mirafiori Carrozzerie plant will be able to produce results only in 2026.The level of production decline in 2025 is higher than expected, Uliano noted.The union chief also urged Stellantis to clarify its strategy for the Maserati brand, including models and volumes, as the brand faces performance issues.The carmaker is expected to announce its first-half results on July 29.On Stocktwits, retail sentiment around Stellantis remained unmoved within ‘neutral’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_1_59_03_PM_png_17daabda43.webp" alt="STLA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on July 7, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>STLA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>STLA stock is trading 5% lower as of Monday noon. The stock is down by 25% this year and by about 50% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/artelo-biosciences-reports-strong-preclinical-data-in-par-with-zoloft-for-experimental-depression-drug/chFtpirR5QR">Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Stellantis N.V

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

EFAS Global X Funds - Global X MSCI SuperDividend EAFE ETF

Fundamentals

Latest EFAS News